These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9674761)

  • 21. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
    Hampel H; Mesulam MM; Cuello AC; Farlow MR; Giacobini E; Grossberg GT; Khachaturian AS; Vergallo A; Cavedo E; Snyder PJ; Khachaturian ZS
    Brain; 2018 Jul; 141(7):1917-1933. PubMed ID: 29850777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease: clinical treatment options.
    Reichman WE
    Am J Manag Care; 2000 Dec; 6(22 Suppl):S1125-32; discussion S1133-8. PubMed ID: 11142177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of cholinergic and memantine treatment in Alzheimer's disease in Finland.
    Virta L; Viramo P
    J Am Geriatr Soc; 2007 Nov; 55(11):1886-7. PubMed ID: 17979907
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacological treatment of dementia.
    Santaguida PS; Raina P; Booker L; Patterson C; Baldassarre F; Cowan D; Gauld M; Levine M; Unsal A
    Evid Rep Technol Assess (Summ); 2004 Apr; (97):1-16. PubMed ID: 15279402
    [No Abstract]   [Full Text] [Related]  

  • 25. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
    Droogsma E; van Asselt D; Diekhuis M; Veeger N; van der Hooft C; De Deyn PP
    Int Psychogeriatr; 2015 Aug; 27(8):1323-33. PubMed ID: 25779465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.
    Gauthier S; Rountree S; Finn B; LaPlante B; Weber E; Oltersdorf T
    J Alzheimers Dis; 2015; 48(2):473-81. PubMed ID: 26402011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research.
    Hampel H; Mesulam MM; Cuello AC; Khachaturian AS; Vergallo A; Farlow MR; Snyder PJ; Giacobini E; Khachaturian ZS
    J Prev Alzheimers Dis; 2019; 6(1):2-15. PubMed ID: 30569080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors.
    Erkinjuntti T; Román G; Gauthier S
    Neurol Res; 2004 Jul; 26(5):603-5. PubMed ID: 15265282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Impact of treatment with acetylcholinesterase inhibitors, valproic acid and antipsychotics on aggressive behaviour in Alzheimer's type dementia].
    Bidzan L; Grabowski J; Dutczak B; Bidzan M
    Psychiatr Pol; 2012; 46(3):361-72. PubMed ID: 23045890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
    Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
    J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to letter from Garcia and colleagues on cholinesterase inhibitors and Alzheimer's disease outcomes.
    Gillette-Guyonnet S; Andrieu S; Nourhashemi F; Reynish E; Vellas B
    J Gerontol A Biol Sci Med Sci; 2007 Jun; 62(6):679-80. PubMed ID: 17595427
    [No Abstract]   [Full Text] [Related]  

  • 33. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholinergic therapies for Alzheimer's disease: progress and prospects.
    Palmer AM
    Curr Opin Investig Drugs; 2003 Jul; 4(7):820-5. PubMed ID: 14619403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options.
    Cummings JL; Tong G; Ballard C
    J Alzheimers Dis; 2019; 67(3):779-794. PubMed ID: 30689575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine.
    Desmidt T; Hommet C; Camus V
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):300-6. PubMed ID: 27651011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs for cognitive loss and dementia.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):155-161. PubMed ID: 28922342
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
    Mizuno S; Kameda A; Inagaki T; Horiguchi J
    Psychiatry Clin Neurosci; 2004 Dec; 58(6):660-5. PubMed ID: 15601392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Future therapeutic approaches to Alzheimer's disease.
    Davis KL
    J Clin Psychiatry; 1998; 59 Suppl 11():14-6. PubMed ID: 9731545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.